Amber Gordon

3.0k total citations · 2 hit papers
14 papers, 1.5k citations indexed

About

Amber Gordon is a scholar working on Genetics, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Amber Gordon has authored 14 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 5 papers in Molecular Biology. Recurrent topics in Amber Gordon's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Amber Gordon is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Amber Gordon collaborates with scholars based in United States and United Kingdom. Amber Gordon's co-authors include John C. Byrd, Amy J. Johnson, Joseph M. Flynn, Jeffrey J. Jones, Kristie A. Blum, Xiaoli Zhang, Asha Ramanunni, Samantha Jaglowski, Ahmed Hamdy and Sarah E. M. Herman and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Amber Gordon

14 papers receiving 1.5k citations

Hit Papers

Bruton tyrosine kinase represents a promising therapeutic... 2011 2026 2016 2021 2011 2017 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
    2011 607 citations Sarah E. M. Herman, Amber Gordon et al. Blood profile →
  2. Ibrutinib treatment improves T cell number and function in CLL patients
    2017 288 citations Meixiao Long, Kyle A. Beckwith et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amber Gordon United States 8 1.2k 792 535 432 357 14 1.5k
Sílvia Marcé Spain 12 1.1k 0.9× 877 1.1× 599 1.1× 458 1.1× 240 0.7× 20 1.6k
Sissy Peterman United States 14 1.1k 0.9× 806 1.0× 322 0.6× 434 1.0× 271 0.8× 16 1.3k
Asha Ramanunni United States 8 800 0.7× 568 0.7× 409 0.8× 310 0.7× 270 0.8× 14 1.1k
Mariela Sivina United States 18 1.5k 1.3× 947 1.2× 778 1.5× 649 1.5× 471 1.3× 39 2.0k
John N. Allan United States 21 803 0.7× 708 0.9× 319 0.6× 206 0.5× 286 0.8× 97 1.1k
Priti Patel United States 17 841 0.7× 699 0.9× 301 0.6× 261 0.6× 411 1.2× 57 1.2k
Antonella Zucchetto Italy 23 1.2k 1.1× 862 1.1× 753 1.4× 492 1.1× 244 0.7× 79 1.8k
Kathryn Humphrey United Kingdom 16 1.0k 0.9× 920 1.2× 369 0.7× 208 0.5× 320 0.9× 52 1.4k
Andrew Greaves United States 11 1.1k 0.9× 780 1.0× 623 1.2× 241 0.6× 140 0.4× 23 1.2k
Nicole Lamanna United States 21 1.4k 1.2× 1.1k 1.4× 536 1.0× 269 0.6× 428 1.2× 113 1.8k

Countries citing papers authored by Amber Gordon

Since Specialization
Citations

This map shows the geographic impact of Amber Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amber Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amber Gordon more than expected).

Fields of papers citing papers by Amber Gordon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amber Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amber Gordon. The network helps show where Amber Gordon may publish in the future.

Co-authorship network of co-authors of Amber Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Amber Gordon. A scholar is included among the top collaborators of Amber Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amber Gordon. Amber Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Heerema, Nyla A., Natarajan Muthusamy, Qiuhong Zhao, et al.. (2020). Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia. Haematologica. 106(6). 1608–1615. 7 indexed citations
2.
Gordon, Amber, et al.. (2019). Anatomy, Shoulder and Upper Limb, Axilla. 2 indexed citations
3.
Mani, Rajeswaran, Bhavani Gopalakrishnan, Xiaokui Mo, et al.. (2018). The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica. 103(8). 1288–1297. 33 indexed citations
4.
Long, Meixiao, Kyle A. Beckwith, Priscilla Do, et al.. (2017). Ibrutinib treatment improves T cell number and function in CLL patients. Journal of Clinical Investigation. 127(8). 3052–3064. 288 indexed citations breakdown →
5.
Heerema, Nyla A., Qiuhong Zhao, Amy S. Ruppert, et al.. (2016). Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients. Blood. 128(22). 4372–4372. 1 indexed citations
6.
Mani, Rajeswaran, Chi‐Ling Chiang, Frank Frissora, et al.. (2016). CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia. Blood. 128(22). 2748–2748. 1 indexed citations
7.
Mani, Rajeswaran, Bhavani Gopalakrishnan, Xiaokui Mo, et al.. (2016). SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model. Blood. 128(22). 580–580. 1 indexed citations
8.
Woyach, Jennifer A., Amy S. Ruppert, Gerard Lozanski, et al.. (2014). Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.. Journal of Clinical Oncology. 32(15_suppl). 7010–7010. 9 indexed citations
9.
Guinn, Daphne, Amy S. Ruppert, Kami J. Maddocks, et al.. (2014). Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib. Blood. 124(21). 3297–3297. 1 indexed citations
10.
11.
Herman, Sarah E. M., Amber Gordon, Erin Hertlein, et al.. (2011). Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 117(23). 6287–6296. 607 indexed citations breakdown →
12.
Herman, Sarah E.M., Rosa Lapalombella, Amber Gordon, et al.. (2011). The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood. 117(16). 4323–4327. 81 indexed citations
13.
Herman, Sarah E.M., Amber Gordon, Emilia Mahoney, et al.. (2010). The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals. Blood. 116(21). 1385–1385. 3 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sílvia Marcé Breakdown of academic impact, for papers by Sissy Peterman Breakdown of academic impact, for papers by Asha Ramanunni Breakdown of academic impact, for papers by Mariela Sivina Breakdown of academic impact, for papers by John N. Allan Breakdown of academic impact, for papers by Priti Patel Breakdown of academic impact, for papers by Antonella Zucchetto Breakdown of academic impact, for papers by Kathryn Humphrey Breakdown of academic impact, for papers by Andrew Greaves Breakdown of academic impact, for papers by Nicole Lamanna
Rankless by CCL
2026